High-grade gliomas, such as glioblastoma and diffuse midline glioma, are currently incurable diseases with an urgent need for novel therapeutic approaches.
High-grade gliomas, including glioblastoma and diffuse midline glioma are the most common malignant brain tumor types and leading causes of brain-tumor-related death in adults and children, respectively.
Stanford researchers in Prof. Michelle Monje's lab have developed a method for treating cognitive impairment (aka brain fog) caused by cancer immunotherapy.
Researchers in Dr. Michelle Monje-Deisseroth's lab at Stanford have identified therapeutic targets for drug development to limit the spread of high-grade gliomas (HGGs).
Researchers in Prof. Michelle Monje-Deisseroth's laboratory have discovered a previously unknown mechanism for glioma tumor growth and invasion that defines a novel set of therapeutic targets.